{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:38:28Z","timestamp":1793723908283,"version":"4.6.1"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1684,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1111\/j.1755-3768.2010.02077.x","type":"journal-article","created":{"date-parts":[[2011,1,21]],"date-time":"2011-01-21T10:37:18Z","timestamp":1295606238000},"page":"452-458","source":"Crossref","is-referenced-by-count":31,"title":["Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity"],"prefix":"10.1111","volume":"89","author":[{"given":"Linda","family":"Moseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mali","family":"Saeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild H.","family":"M\u00f8rch-Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana M.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eylert","family":"Brodtkorb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Midelfart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,21]]},"reference":[{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.ophtha.2004.03.036","article-title":"Characteristic retinal atrophy with secondary \u201cinverse\u201d optic atrophy identifies vigabatrin toxicity in children","volume":"111","author":"Buncic","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bjo.2006.113118","article-title":"Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy","volume":"91","author":"Chai","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/eye.2009.64","article-title":"Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy","volume":"24","author":"Clayton","year":"2009","journal-title":"Eye"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2007.01249.x","article-title":"Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy","volume":"49","author":"Conway","year":"2008","journal-title":"Epilepsia"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0161-6420(99)90345-7","article-title":"Symptomatic and asymptomatic visual loss in patients taking vigabatrin","volume":"106","author":"Daneshvar","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1167\/iovs.08-3237","article-title":"Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy","volume":"50","author":"Durbin","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"BMJ"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB8|cit8","article-title":"The Effect of Vigabatrin on the ERG in Patients With Infantile Spasms","volume":"47","author":"Eklund","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1034\/j.1600-0420.2003.00125.x","article-title":"Characterization of vigabatrin-associated optic atrophy","volume":"81","author":"Frisen","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0002-9394(00)00763-7","article-title":"Separating the retinal electrophysiologic effects of vigabatrin. treatment versus field loss","volume":"130","author":"Harding","year":"2000a","journal-title":"Am J Ophthalmol"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1212\/WNL.55.3.347","article-title":"Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss","volume":"55","author":"Harding","year":"2000b","journal-title":"Neurology"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00023210-200115030-00005","article-title":"Visual field defects with vigabatrin: epidemiology and therapeutic implications","volume":"15","author":"Kalviainen","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1528-1167.2006.00422.x","article-title":"Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose","volume":"47","author":"Kinirons","year":"2006","journal-title":"Epilepsia"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10633-007-9108-3","article-title":"Full-field ERG and visual fields in patients 5\u2003years after discontinuing vigabatrin therapy","volume":"117","author":"Kjellstrom","year":"2008","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.50.3.614","article-title":"Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings","volume":"50","author":"Krauss","year":"1998","journal-title":"Neurology"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jnnp.67.6.716","article-title":"Visual field defects associated with vigabatrin therapy","volume":"67","author":"Lawden","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ophtha.2008.09.047","article-title":"Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity","volume":"116","author":"Lawthom","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1528-1157.2001.28600.x","article-title":"Vigabatrin visual toxicity: evolution and dose dependence","volume":"42","author":"Malmgren","year":"2001","journal-title":"Epilepsia"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/bjo.85.1.110k","article-title":"The wide field multifocal ERG reveals a retinal defect caused by vigabatrin toxicity?","volume":"85","author":"McDonagh","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1034\/j.1600-0420.2000.078005580.x","article-title":"Visual field defects in patients taking vigabatrin","volume":"78","author":"Midelfart","year":"2000","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1017\/S0317167100004443","article-title":"Visual defects associated with vigabatrin: a study of epileptic argentine patients","volume":"32","author":"Moreno","year":"2005","journal-title":"Can J Neurol Sci"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/WNL.57.10.1916","article-title":"No reversion in vigabatrin-associated visual field defects","volume":"57","author":"Nousiainen","year":"2001","journal-title":"Neurology"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/jnnp.70.6.787","article-title":"Visual field loss associated with vigabatrin: pathological correlations","volume":"70","author":"Ravindran","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 3A","key":"10.1111\/j.1755-3768.2010.02077.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/eye.2000.83","article-title":"Vigabatrin-associated visual field defects in children","volume":"14","author":"Russell-Eggitt","year":"2000","journal-title":"Eye"},{"issue":"Suppl 1","key":"10.1111\/j.1755-3768.2010.02077.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1111\/j.1365-2125.1989.tb03456.x","article-title":"Clinical pharmacology of vigabatrin","volume":"27","author":"Schechter","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.exer.2008.06.002","article-title":"Topography of retinal damage in light-exposed albino rats","volume":"87","author":"Tanito","year":"2008","journal-title":"Exp Eye Res"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","article-title":"Characteristics of a unique visual field defect attributed to vigabatrin","volume":"40","author":"Wild","year":"1999","journal-title":"Epilepsia"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1167\/iovs.05-0854","article-title":"Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer","volume":"47","author":"Wild","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1111\/j.1755-3768.2010.02077.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1528-1167.2008.01988.x","article-title":"Vigabatrin: 2008 update","volume":"50","author":"Willmore","year":"2009","journal-title":"Epilepsia"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-3768.2010.02077.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1755-3768.2010.02077.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:48:24Z","timestamp":1625572104000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-3768.2010.02077.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,21]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1755-3768.2010.02077.x","relation":{},"ISSN":["1755-375X"],"issn-type":[{"value":"1755-375X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1,21]]}}}